US Food and Drug Administration (USFDA) has concluded inspection at Shilpa Medicare’s Active Pharmaceutical Ingredients (API) sites (Unit I and Unit II) which are located at Raichur District, Karnataka between February 3, 2020 and February 7, 2020. The inspection concluded with 'ZERO' observations.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
